Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys

Virology

Volumn 316, Issue 1, 2003, Pages 55-63

  Marchevsky, Renato S ^a   Freire, Marcos S ^a   Coutinho, Evandro S F ^a   Galler, Ricardo ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

17DD vaccine virus; Monkey neurovirulence test; Yellow fever vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE; YELLOW FEVER VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; EXPERIMENTAL TEST; FEMALE; GENETIC VARIABILITY; HISTOLOGY; HISTOPATHOLOGY; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOGENICITY; INDIVIDUALITY; LD 50; MALE; MONKEY NEUROVIRULENCE TEST; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEROCONVERSION; STRAIN DIFFERENCE; SUBSTANTIA NIGRA; VIREMIA; VIRUS ATTENUATION; VIRUS ENCEPHALITIS; VIRUS IMMUNITY; VIRUS STRAIN; VIRUS VIRULENCE; YELLOW FEVER FLAVIVIRUS;

ANIMALIA; MACACA MULATTA; YELLOW FEVER VIRUS (STRAIN 17D);

EID: 0242289408     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00583-X     Document Type: Article

References (28)

1. Armitage P., Berry G. Statistical Methods in Medical Research. third ed:1994;620 Blackwell Scientific Publications, Oxford.
2. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 358:2001;121-122.
3. Fox J.P., Cabral A.S. The duration of immunity following vaccination with the 17D strain of yellow fever virus. Am. J. Hyg. 37:1943;93-120.
4. Fox J.P., Lennette E.H., Manso C., Souza Aguiar J.R. Encephalitis in man following vaccination with 17D yellow fever virus. Am. J. Hyg. 36:1942;117-142.
5. Fox J.P., Cunha J.F., Kossobudzki S.L. Additional observations on the duration of humoral immunity following vaccination with the 17D strain of yellow fever virus. Am. J. Hyg. 47:1948;64-70.
6. Fox F.P., Penna H.A. Behavior of 17D yellow fever virus in Rhesus monkeys. Relation to substrain, dose and neural or extraneural inoculation. Am. J. Hyg. 38:1943;152-172.
7. Hedges V.L., Olkim I. Statistical Methods for Meta-Analysis. 1985;369 Academic Press, London.
8. Galler R., Post P.R., Santos C.N.D., Ferreira I.I. Genetic variability among yellow fever virus 17D substrains. Vaccine. 16:1998;1024-1028.
9. Galler R., Pugachev K.V., Santos C.L.S., Ochran S.W., Jabo,r A.V., Rodrigues S.G., Marchevsky R.S., Freire M.S., Almeida L.F.C., Cruz A.C.R., Yamamura A.M.Y., Rocco I.M., Travassos da Rosa E.S., Souza L.T.M., Vasconcelos P.F.C., Guirakhoo F., Monath T.P. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 290:2001;309-319.
10. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., Arroyo J., Georgakopoulos K., Catalan J., Monath T.P. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol. 74:2000;5477-5485.
11. Guirakhoo F., Pugachev K., Arroyo J., Miller C., Zhang Z.X., Weltzin R., Georgakopoulos K., Catalan J., Ocran S., Draper K., Monath T.P. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates . Virology. 298:2002;146-159.
12. Jennings A.D., Gibson C.A., Miller B.R., Mathews J.H., Mitchell C.J., Roehrig J.T., Wood D.J., Taffs F., Sil B.K., Whitby S.N., Minor P.D., Monath T.P., Barrett A.D.T. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J. Infect. Dis. 169:1994;512-518.
13. Levenbook I.S., Pellen L.J., Elisberg B.L. The monkey safety test for neurovirulence of YF vaccines the utility of quantitative clinical evaluation and histological examination . J. Biol. Stand. 15:1987;305-313.
14. Marchevsky R.S., Mariano J., pFerreira V.S., Almeida E., Cerqueira M.J., Carvalho R., Pissurno J.W., Travassos da Rosa A.P.A., Simões M.C., Santos C.N.D., Ferreira I.I., Muylaert I.R., Mann G.F., Rice C.M., Galler R. Phenotypic analysis of yellow fever virus derived from complementary DNA. Am. J. Trop. Med. Hyg. 52:1995;75-80.
15. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., Shieh W., Zaki S.R., Al-Sanouri I., Cutrona A.F., Ray G., Weld L.H., Cetron M.S. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination a report of four cases . Lancet. 358:2001;98-104.
16. Monath T.P., Brinker K.R., Chandler F.W., Kemp G.E., Cropp C.B. Pathophysiologic correlations in a rhesus monkey model of yellow fever. Am. J. Trop. Med. Hyg. 30:1981;431-443.
17. Monath T.P., Kinney R.M., Schlesinger J.J., Brabdriss M.W., Bres P. Ontogeny of yellow fever 17D vaccine RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide . J. Gen. Virol. 64:1983;627-637.
18. Monath T.P. Yellow fever. Plotkin S., Orenstein W. Vaccines. 1999;815-998 Saunders, Philadelphia.
19. Monath T.P., Levenbook I., Soike K., Zhang Z.X., Rattterree M., Draper K., Barrett A.D.T., Nichols R., Weltzin R., Arroyo J., Guirakhoo F. Chimeric yellow fever 17D-Japanese encephalitis virus vaccine dose-response effectiveness and extended safety testing in rhesus monkeys . J. Virol. 74:2000;1742-1751.
20. Monath T.P., McCarthy K., Bedford P., Johnson C.T., Nichols R., Yoksan S., Marchesani R., Knauber M., Wells K., Arroyo J., Guirakhoo F. Clinical proof of principle for Chimeri Vax recombinant live, attenuated vaccines against flavivirus infections . Vaccine. 20:2002;1004-1018.
21. Nathanson N., Gittelsohn A.M., Thind I.S., Price W.H. Histological studies of the monkey neurovirulence of group B arboviruses III relative virulence of selected viruses . Am. J. Epidemiol. 85:1966;503-517.
22. Poland J.D., Calisher C.H., Monath T.P., Downs W.G., Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ. 59:1981;895-900.
23. Post P.R., Carvalho R., Freire M.S., Galler R. The early use of yellow fever virus strain 17D for vaccine production in Brazil. Mem. Inst. Oswaldo Cruz. 96:2001;849-857.
24. Pugachev K.V., Ocran S.W., Guirakhoo F., Furby D., Monath T.P. Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine. 20:2002;996-999.
25. Ryman K.D., Ledger T.N., Weir R.C., Schlesinger J.J., Barrett A.D.T. Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes. J. Gen. Virol. 78:1997;1353-1356.
26. Vasconcelos P.F.C., Luna E.J.A., Galler R., Silva J.L., Coimbra T.L., Barros V.L.R., Monath T.P., Rodrigues S.G., Laval C., Costa Z.G., Vilela M.F.G., Santos C.L.S., Papaiordanou C.M.O., Alves V.A., Andrade L.D., Sato H.K., Rosa E.S.T., Froguas G.B., Lacava E., Almeida L.M.R., Cruz A.C.R., Rocco I.M., Santos R.T.M., Oliva O.F.P. Serious adverse events associated with yellow fever 17DD vaccine in Brazil report of two cases . Lancet. 358:2001;91-97.
27. The immunological basis for immunization 8: yellow fever. 1993;World Health Organization, Geneva.
28. World Health Organization (WHO) 1998. Requirements for yellow fever vaccine. WHO Tech. Rep. Ser. 872: 31-68.